Navigation Links
MedCath Corporation Reports First Quarter Earnings
Date:2/7/2008

r's results, income from operations increased 15.6%. Adjusted EBITDA in the first quarter of fiscal 2008 increased 12.2% to $23.5 million from $20.9 million in the first quarter of fiscal 2007, which included $2.1 million attributable to HMC. Excluding this amount from prior year's results, Adjusted EBITDA increased 25.0%. Income from continuing operations was $3.3 million, or $0.15 per diluted share, in the first quarter of fiscal 2008, compared to income from continuing operations of $254,000, or $0.01 per diluted share, in the first quarter of fiscal 2007. MedCath's first quarter of fiscal 2007 income from continuing operations would have been $0.7 million, or $0.03 per diluted share, had HMC been accounted for as an equity investment in the first quarter of fiscal 2007.

MedCath's operating results for the quarter ended December 31, 2007 reflect the following items that collectively negatively impacted net revenue $0.2 million, Adjusted EBITDA $0.6 million and diluted earnings per share $0.02:

-- A $0.2 million, or net impact of $0.01 per diluted share, decrease in

net revenue and Adjusted EBITDA related to settlement of third-party

cost reports during the quarter, and

-- A $0.4 million, or net impact of $0.01 per diluted share, decrease in

Adjusted EBITDA related to senior management severance expense and

higher professional fees incurred for implementation of the Company's

business continuity plan during the quarter.

MedCath's first quarter of fiscal 2007 results were negatively impacted by a $2.7 million reduction in net revenue and Adjusted EBITDA and a $3.7 million, or $0.18 per diluted share, reduction in income from continuing operations.

Share-based compensation expense totaled $3.7 million, or $0.12 per diluted share, in the first quarter of fiscal 2008, compared to $1.0 million, or $0.03 per diluted share, in the first quarter of fiscal 2007. Pre-opening expenses totale
'/>"/>

SOURCE MedCath Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. MedCath Corporation to Hold Conference Call on First Quarter Results
2. MedCath Corporation to Present at the 26th Annual JPMorgan Healthcare Conference
3. MedCath Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
4. MedCath Corporation Reports Fourth Quarter Earnings and Outlook for Fiscal 2008
5. Otter Tail Corporation Reports Record Revenues and Net Income From Continuing Operations for 2007; Earnings Per Share of $1.78; Board Approves Dividend Increase
6. STERIS Corporation Promotes Timothy L. Chapman to Group President of Healthcare
7. Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management
8. CRH Medical Corporation announces substantial increase in patient visits
9. Medical Simulation Corporation and the American Board of Internal Medicine Introduce New Simulation for Physician Assessment and Evaluation
10. Providence Service Corporation to Present at the 2008 UBS Global Healthcare Services Conference on February 11
11. Triple-S Management Corporation to Present at UBS Global Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)... After suffering from women,s hair loss...rowing back and she,s sharing her progress and the... women through the release of her video diaries wh... and during her treatment. , ...r loss sufferer Zsanett Siklosi has released the ...
(Date:11/23/2009)...O,Pa.,Nov.23/PRNewswire-FirstCall/--InfoLogix,Inc....risemobilitysolutionsforthehealthcareandcommercial...identofManagedServicesatSiemensHealthServices,hasj...Services. ,, (Logo: http://www.newscom.com/cgi-...entofStrategicHealthcareServicesforInfoLogix,Mr.Wa...
(Date:11/23/2009)...rs of cancer patients and survivors treated with c...t often become chronic conditions, hindering patie...ists at the University of Rochester Medical Center...xperienced sleep troubles at nearly three times th...more prevalent in younger patients and those with ...
(Date:11/23/2009)...w their odds drop by 63 percent with moderate-to-h...23 (HealthDay News) -- Moderate-to-high intensity ...elp reduce stroke risk in older men but not in wom...most 3,300 men and women, average age 69, in Manha...g that time, there were 238 strokes among the part...
(Date:11/23/2009)...p weaknesses of drug approval process in United St...3 (HealthDay News) -- Problems with the popular ar...eart attack, stroke and death, were known for year...market in 2004, a new report says. , Contrary ...ngerous side effects were evident in 2000, a year ...
Breaking Medicine News(10 mins):Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 2Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 3Health News:Insomnia prevalent among cancer patients who receive chemotherapy 2Health News:Vigorous Exercise Cuts Stroke Risk for Men, Not Women 2Health News: Vioxx Problems Known Years Before Recall 2Health News: Vioxx Problems Known Years Before Recall 3Health News: Vioxx Problems Known Years Before Recall 4
...with cervical spinal injury may have more damage t...hed in the Annals of Emergency Medicine, say that ...n patients over and above the normal X-rays.// ...re than a third of patients who were thought to ha...
..., researchers from University of South Florida had...Gerontology: Psychological Sciences that the more ... may have a role to play in reducing the risk of d... and dementia in general. Researchers had discover...
Dengue, the mosquito-transmitted lethal disease that has claimed 15 lives and afflicted 1,000 people in West Bengal so far, has been declared an epidemic by the state government.// State Health Di
...tment of had discovered a new way to test the stem...// The researchers had used a non-invasive i... trace stem cells’ destinations after being inject... myocardial infarctions in seven dogs, six of whic...
...l significantly reduces the spread of gastrointest...ilies studied, half of the families, which used th... in the spread of illness related to the gastroint...zer and educational materials on hand hygiene. The...
...ve that governs the flow of blood into a large blo...o various organs of the body. // It prevents the b...est of the body. The effective functioning of.... The defect can be present right form birth or it...
Other Medicine News:Health News:Alcohol based sanitizer found to reduce illness in families 2Health News:Percutaneous aortic valve replacement- a revolution in Cardiac Surgery 2
(Date:11/23/2009)...,Nov.23/PRNewswire-USNewswire/--JubilantOrganosys,...nResearchInstitutetodayannouncedajointventurethatw...ablingtechnologiesintheareasofOncology,MetabolicDi...bitragedandleveragedpartnershipthatwillacceleratet...wide.AMemorandumofUnderstandingwassignedtodayinWas...
(Date:11/23/2009)...-BioTrendsResearchGroup,Inc.releasedWave2ofits La...lti-phasesyndicatedmarketresearchprojecttrackingth...efirstsixmonthsofproductavailability.Eachwaveofthe...ephrologistsandqualitativeinformationfromasubsetof...touse,reasonstouse,typicalpatienttypes,productperc...
(Date:11/23/2009)...rstCall/--CordBloodAmerica,Inc.(OTCBulletinBoard:C...any( http://www.cordblood-america.com )focusedonbr...linsurancepolicy,tofamiliesnationwideandinternatio...withCEOandco-founderMatthewSchisslerisnowavailable...e/2875811 . ,, Intheinterview,Mr.Schisslerupdat...
Breaking Medicine Technology:Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 2Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 3Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 4Reported Use of AMAG's Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are 'On the Verge' of Use 2Canadian Cancer Society Selects Branded Merchandise Solutions From Boundless Network 61066 1Canadian Cancer Society Selects Branded Merchandise Solutions From Boundless Network 61066 2Canadian Cancer Society Selects Branded Merchandise Solutions From Boundless Network 61066 3Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16 2009 14777 1Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16 2009 14777 2PLC Systems Reports Third Quarter 2009 Results 3B Announces Distribution Agreement for RenalGuard 28R 29 in Brazil 6136 1PLC Systems Reports Third Quarter 2009 Results 3B Announces Distribution Agreement for RenalGuard 28R 29 in Brazil 6136 2PLC Systems Reports Third Quarter 2009 Results 3B Announces Distribution Agreement for RenalGuard 28R 29 in Brazil 6136 3PLC Systems Reports Third Quarter 2009 Results 3B Announces Distribution Agreement for RenalGuard 28R 29 in Brazil 6136 4PLC Systems Reports Third Quarter 2009 Results 3B Announces Distribution Agreement for RenalGuard 28R 29 in Brazil 6136 5PLC Systems Reports Third Quarter 2009 Results 3B Announces Distribution Agreement for RenalGuard 28R 29 in Brazil 6136 6
...to Timeline for Second Pivotal Phase 3 Trial CL-05... Advanced Life,Sciences Holdings, Inc. , today ann...ata from Trial CL-06, the first of two,pivotal Pha... and,effectiveness of cethromycin, a novel once-a-...uired pneumonia (CAP). The Company,also provided a...
..., July 2, 2007-Women with at least three sites of,...times more likely,than average women to develop br...c Cancer Center led study of women with atypical,h... 1 issue of the,Journal of Clinical Oncology., Sev...erplasia,(also called atypia) in breast tissue is ...
Other Medicine Technology:Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 2Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 3Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 4Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 5Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 6Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 7Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast,Cancer Risk Prediction in Women with Atypia 2Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast,Cancer Risk Prediction in Women with Atypia 3
Carter Sphere Introducer and Holder
Symblepharon Ring - Medium
Oval Sponge Implants - 3.0 x 5.0 x 100 mm
Grooved Segmental Buckle - 2.3 x 6.4 x 80 mm
Medicine Products: